Skip to main content
Veterinary Medicines

RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS

Authorised
  • Cephalexin benzathine

Product identification

Medicine name:
RILEXINE DC 375 MG INTRAMAMMARY SUSPENSION FOR DRY COWS
Rilexine DC 375 mg suspensão intramamária para vacas secas
Active substance:
  • Cephalexin benzathine
Target species:
  • Cattle (cow)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Cephalexin benzathine
    500.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (cow)
      • Meat and offal
        4
        day
      • Milk
        43
        day
      • Milk
        12
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51DB01
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:
  • Box of 24 x 8g intramammary syringes and 24 cleaning towels
  • Box of 60 x 8g intramammary syringes and 60 cleaning towels
  • Box of 12 x 8g intramammary syringes and 12 cleaning towels

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Haupt Pharma Latina S.r.l.
  • Virbac
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 1505/01/22DFVPT
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0438/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 17/08/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."